Faculty profile

Andrea Eisen

ResearcherUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

Andrea Eisen

Researcher

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
78 publications in the last five years, latest in 2026.
Senior (last) author on 1 recent paper, a sign of leading a research group.
Principal investigator on 6 research grants (6 CIHR), most recently in 2025.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

164

Publications

7,346

Citations

212

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Breast Cancer Genetic Testing Treatment Brca1 Brca2 Cascade Genetic Testing Digital Platform Family

Latest papers

Menopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2
Journal of the National Cancer Institute · 2026
Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in BRCA1 or BRCA2
Journal of Clinical Oncology · 2026
Appropriate Treatment for Stage 1 and 2 Her2-Positive and Triple-Negative Breast Cancer by Immigration Status in Ontario, Canada
Clinical Breast Cancer · 2026

All 164 publications

Latest funding

Evaluating Outcomes after Risk-reducing Oophorectomy in BRCA carriers
CIHR · 2026 · Co-investigator
$647,356
Development of a Notification and Support System for Genetic Testing in Women with Prevalent Breast Cancer
CIHR · 2025 · Principal investigator
$745,875
Establishing a Global Cohort to Investigate ATRIP-Associated Cancer Risk and Outcomes
CIHR · 2025 · Co-investigator
$1,044,225

All 15 grants and awards

From the 150 most recent of 164 publications.

Menopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2

Kotsopoulos J, Seca M, Gronwald J, Huzarski T, Møller P, Kim RH, Singer CF, Karlan B, Aeilts A, Ramón y Cajal T

Journal of the National Cancer Institute202611 citations

DOI: 10.1093/jnci/djaf363

Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in BRCA1 or BRCA2

Apostol AI, Gronwald J, Cybulski C, Kim RH, Møller P, Karlan BY, Bordeleau L, Schrader I, Ramón y Cajal T, Pal T

Journal of Clinical Oncology20265 citations

DOI: 10.1200/jco-25-01648

Appropriate Treatment for Stage 1 and 2 Her2-Positive and Triple-Negative Breast Cancer by Immigration Status in Ontario, Canada

Fatiregun O, Sutradhar R, Podolsky S, Eisen A, Paszat L, Rakovitch E

Clinical Breast Cancer20264 citations

DOI: 10.1016/j.clbc.2025.07.013

“Where do I go from here?” Navigating a lifelong road without a map: the care experiences of hereditary cancer patients

Butkowsky C, Carroll JC, Aronson M, Sam J, Reble E, Clausen M, Gopalakrishnan R, Sparkes B, Rajeziesfahani S, Aguda V

European Journal of Human Genetics20261 citations

DOI: 10.1038/s41431-026-02069-y

High-Risk Benign Breast Lesions: An Ontario Health (Cancer Care Ontario) Recommendations Report

Eisen A, Bane A, Causer P, Cordeiro E, Fienberg S, Kornecki A, Kulkarni A, Hong NL, Mancuso T, Muradali D

Current Oncology2026First author

DOI: 10.3390/curroncol33020067

Opportunistic screening for broad range of medically relevant secondary findings: Laboratory benefits and burdens

Mighton C, Reble E, Sam J, Kodida R, Shickh S, Clausen M, Hirjikaka D, Grewal S, Panchal S, Piccinin C

Genetics in Medicine2026

DOI: 10.1016/j.gim.2025.101599

Perspectives from a multi-stakeholder workshop for implementing a risk-stratified breast cancer screening program in Canada

Safieh-Garabedian N, Antoniou AC, Brooks J, Carroll J, Cavaillé M, Chiquette J, DeCoteau M, Doyle G, Eisen A, Eloy L

Communications Medicine2026

DOI: 10.1038/s43856-026-01582-x

Contribution of Risk Factors, Including Polygenic Score, to the Multifactorial Risk Assessment for the Implementation of Personalized Breast Cancer Screening: Insights from the PERSPECTIVE: Integration and Implementation Project

Yang X, Usher-Smith JA, Blackmore KM, Brooks JD, Bell KA, Carver T, Chang A, Chiquette J, Easton DF, Eisen A

Cancers2026

DOI: 10.3390/cancers18091482

Mammographic screening and time to breast cancer diagnosis among immigrants and long-term residents in Ontario

Fatiregun OA, Sutradhar R, Podolsky S, Eisen A, Paszat L, Rakovitch E

BMC Cancer2026

DOI: 10.1186/s12885-026-15693-0

Projected Benefit of Bilateral Salpingo-Oophorectomy by Age in BRCA Carriers.

Giannakeas V, Apostol AI, Diella C, Dave N, Gronwald J, Fruscio R, Karlan BY, Cybulski C, Singer CF, Møller P, Kim RH, Bordeleau L, Ramón Y Cajal T, Pal T, Eisen A, Couch FJ, Zakalik D, Metcalfe K, Tung N, Aeilts A, Sun P, Lubinski J, Kotsopoulos J, Narod SA, Hereditary Ovarian Cancer Clinical Study Group

JAMA surgery2026

DOI: 10.1001/jamasurg.2026.4356 PMID: 42776544

Something wrong or missing on this profile? Suggest a correction

Andrea Eisen

Research

Latest papers

Latest funding

Menopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2

Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in BRCA1 or BRCA2

Appropriate Treatment for Stage 1 and 2 Her2-Positive and Triple-Negative Breast Cancer by Immigration Status in Ontario, Canada

“Where do I go from here?” Navigating a lifelong road without a map: the care experiences of hereditary cancer patients

High-Risk Benign Breast Lesions: An Ontario Health (Cancer Care Ontario) Recommendations Report

Opportunistic screening for broad range of medically relevant secondary findings: Laboratory benefits and burdens

Perspectives from a multi-stakeholder workshop for implementing a risk-stratified breast cancer screening program in Canada

Contribution of Risk Factors, Including Polygenic Score, to the Multifactorial Risk Assessment for the Implementation of Personalized Breast Cancer Screening: Insights from the PERSPECTIVE: Integration and Implementation Project

Mammographic screening and time to breast cancer diagnosis among immigrants and long-term residents in Ontario

Projected Benefit of Bilateral Salpingo-Oophorectomy by Age in BRCA Carriers.

Frequent collaborators

Andrea Eisen

Joanne Kotsopoulos

Louise Bordeleau

Maureen Trudeau

Kelly Metcalfe

Jordan Lerner-Ellis

Yvonne Bombard

Frances Wright

Nicole Look Hong

Barry Rosen

Jacques Simard

Hermann Nabi

Tulin Cil

Kasmintan Schrader

Rinku Sutradhar

Michael Wolfson

Yann Joly

Muriel Brackstone

Eva Grunfeld

Lawrence Paszat

Rossanna Pezo

Julie Hallet

Eileen Rakovitch

William Foulkes

Andreas Laupacis

Natalie Coburn

Vasily Giannakeas

Daniel Moore Freitas Palhares

Greg Stanisz

Som Mukherjee

Meredith Vanstone

Mark Norman Levine

Timothy Whelan

Edward Passos

John Agzarian

Paul Engels

Wojtek Wiercioch

Dennis Hong

Elaine McWhirter

Bobby Shayegan